NEW YORK, May 15, 2018 /PRNewswire/ --
According to data published by Energias Market Research, the global medical cannabis market is projected to grow significantly
from USD 8.28 billion in 2017 to USD 28.07 billion in 2024 and at a
CAGR of 19.1% from 2018 to 2024. There are several factors driving the advances of the medical cannabis market, including
increasing recognition of medical benefits, stronger demand for cannabis in the treatment of various diseases, and rising number
of research and development activities. Sales of cannabis products for adult-use (recreational) are also expected to increase, as
California's new cannabis laws went into effect earlier this year. While California is the largest market, Canada is projected to show strong sales
as well. Deloitte's report projects the Canadian market will be worth at least $5B in sales in
2018. Scythian Biosciences Corp (OTC: SCCYF), Cara Therapeutics Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals, Inc. (NASDAQ:
ZYNE), Cronos Group Inc. (NASDAQ: CRON), Aurora Cannabis Inc. (OTC: ACBFF)
Viridian Capital President Scott Greiper told Benzinga that the cannabis industry received
$1.23 billion investments in the first five weeks of 2018, up from $178
million a year earlier. Viridian Capital Advisors' Vice President Harrison Phillips said:
"Investments in cultivation and retail this year have been driven predominantly by the Canadian player. This has been happening
pretty consistently from late 2016 through 2017. This reflects the necessity to scale cannabis businesses, to get some kind of
advantage, and to explore strategic opportunities, both through acquisitions and international expansion."
Scythian Biosciences Corp (OTCQB: SCCYF) is also listed on the TSX Venture Exchange under the ticker (TSX-V: SCYB).
Just last week the company announced breaking news that, "the Company has entered into a business combination agreement (the
"Agreement") with MMJ International Investments Inc. ("MMJ" or "MMJ International"), owner of Argentina-based ABP S.A. ("ABP"), a pharmaceutical import and distribution company with a license to import,
sell and distribute medical products and derivatives in Argentina. ABP also holds a license to
import CBD oil into Argentina (the "License"). Under the terms of the Agreement, Scythian
will acquire all of the issued and outstanding common shares of MMJ by way of a three-cornered amalgamation (the "Transaction")
whereby MMJ will amalgamate with a wholly-owned subsidiary of the Company. In consideration, Scythian will issue an aggregate of
6,176,320 common shares of the Company to the shareholders of MMJ. The Agreement supersedes the non-binding letter of intent
between Scythian and MMJ previously announced on March 12, 2018, which was extended on March 29, 2018, and extended again on May 1, 2018.
The Transaction is subject to a number of conditions, including approval of the shareholders of MMJ and approval from the TSX
Venture Exchange ("TSXV"). The Transaction will not constitute a "Reverse-Takeover" of Scythian under the policies of the TSXV.
"With this Agreement, Scythian now has access to Argentina's network of hospitals, doctors,
retail pharmacies, private health providers and public health system," said Rob Reid, CEO of
Scythian. "We are thrilled to have accomplished this significant step forward in the Company's expansion efforts and are eager to
work with MMJ to develop quality medical cannabis backed by Argentina's top health researchers
and institutions."
ABP has had a strong platform from its distribution and retail business to build on, having had revenues in excess of
USD$10,000,000 per year since 2014, with over USD$11,000,000 in 2017.
Scythian, working with ABP, will focus on continuing to build out ABP's distribution and retail sales network, while
strategically leveraging the License for expansion purposes.
On April 9, 2018, Scythian announced that ABP had received its license to import CBD oil for
research and development purposes. Shortly after this, ABP issued its first purchase order of CBD oil from Aphria Inc. ("Aphria")
to be imported into Argentina for use in pioneering clinical studies conducted by Argentina's top neurologists and pediatric specialists at the Dr. Juan P. Garrahan Pediatric Hospital. The
study, which will be conducted over 2.5 years, is investigating the use of cannabis in treating refractory epilepsy in children
and will determine the product's pharmacokinetics for the optimization of dosage in future treatments. Additionally, with the
support of Scythian and ABP, a training program will be conducted during and after the study to train and educate a network of
specialized doctors across multiple provinces in Argentina using Aphria's pharmaceutical grade
medical cannabis.
"Now that a binding agreement to acquire MMJ International has been finalized, we can focus our efforts on the research and
development of pharmaceutical grade medical cannabis in South America," said CEO Rob Reid. "We are eager to begin making a positive global impact on the lives of countless patients in
need."
Cara Therapeutics Inc. (NASDAQ: CARA) is a clinical-stage biopharmaceutical company focused on developing and
commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid
receptors (KORs). Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS
cannabinoid receptors. The main naturally occurring ligands for this system, anandamide and 2-arachidonoylglycerol (2-AG),
activate a number of cannabinoid receptors, including CB1 and CB2 receptors. Cara's most advanced CB compound, CR701, is in
preclinical development.
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) is a clinical-stage specialty neuropsychiatric pharmaceutical company
dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare or
near-rare neuropsychiatric disorders with high unmet medical needs. Recently, the company reported financial results for the
first quarter ended March 31, 2018 and provided an overview of recent operational highlights. The
Company expects to enroll approximately 200 pediatric and adolescent patients in the U.S., Australia and New Zealand into a single pivotal study to support an NDA for
ZYN002 in FXS. The primary and key secondary endpoints for the study will assess observable behaviors in patients with FXS as
reported by the caregiver using certain subscales of the validated Aberrant Behavior Checklist in Fragile X syndrome (ABC-FXS).
Data are expected in 2019. FXS affects approximately 71,000 people in the U.S. It is the leading known cause of inherited
intellectual disability and Autism Spectrum Disorder, with symptoms including significant behavioral, social and cognitive
deficits.
Cronos Group Inc. (NASDAQ: CRON) is a globally diversified and vertically integrated cannabis company with a presence
across four continents. The Company operates two wholly-owned Canadian licensed producers regulated under Health Canada's Access
to Cannabis for Medical Purposes Regulations: Peace Naturals Project Inc., which was the first non-incumbent medical
cannabis license granted by Health Canada and Original BC Ltd. (British Columbia), which is
based in the Okanagan Valley. On April 30, 2018, the company announced financial results for the
fourth quarter and fiscal year ended December 31, 2017. Sales increased by $3.5 million, or 636%, to $4.1 million in FY 2017. The Company completed
significant improvements to the three pre-existing indoor production facilities at Peace Naturals Project Inc., to increase
production capacity and efficiency. These facilities are now fully operational. Construction of building 4, a 286,000
sq. ft. production facility, remains on schedule and production is expected to commence in the second half of 2018.
Aurora Cannabis Inc. (OTCQX: ACBFF) and MedReleaf Corp. on Monday announced that they have entered into a definitive
arrangement agreement whereby Aurora intends to acquire all of the issued and outstanding common shares of MedReleaf in an
all-share transaction valued at approximately C$3.2 billion on a fully diluted basis. The proposed
Transaction brings together two of Canada's premier cannabis companies with fully-aligned
strategic visions and production philosophies, as well as complementary assets, distribution networks, products, and
capabilities. The combined company will meet what Aurora and MedReleaf management teams consider to be the critical success
factors in the industry, creating a powerful platform for accelerated growth on a global scale.
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in
this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information
posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality
and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not
offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with
financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique
financial newswire and media platform. For scythian biosciences corp. financial news dissemination and PR services,
FinancialBuzz.com has been compensated four thousand dollars by winning media. Our fees may be
either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination
thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on
or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments
for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site
or continue to post information about any companies the information contained herein is not intended to be used as the basis for
investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is
not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for
any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other
materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of
their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance,
and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound
by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com
constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment
strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is
solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives,
other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and
legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless
of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be
reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please
visit: http://www.financialbuzz.com.
For further information:
info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com